Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06430190

Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata

Sponsor: Zhangyu Bu

View on ClinicalTrials.gov

Summary

This is a prospective, randomized, open-label, controlled study, aiming to enroll 30 patients with Condylomata Acuminata. The study consists of two phases: a treatment phase (Weeks W1-W12) and an observation phase (Weeks W13-W24). Eligible patients will be randomly allocated into three groups at a ratio of 1:1:1: Test Group 1, Test Group 2, or the Control Group. And clinical cure, recurrence rates, adverse events, vital signs, laboratory tests, drug exposure doses, premature withdrawals will be analyzed.

Official title: A Prospective, Exploratory Study to Evaluate the Efficacy of Peginterferon α-2b Injection Combined With Carbon Dioxide(CO2) Laser in the Treatment of Condylomata Acuminata

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-07

Completion Date

2025-12

Last Updated

2024-06-20

Healthy Volunteers

Conditions

Condylomata Acuminata

Interventions

DRUG

Peginterferon α-2b injection

Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.

DRUG

Peginterferon α-2b injection

Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.

OTHER

CO2 laser

On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.

Inclusion Criteria: * Patients must be between 18 and 65 years old. * Patients with positive of human papillomavirus(HPV) nucleic acid test and acetowhite test, were diagnosed as condyloma acuminatum according to clinical manifestations and epidemiological history. * Patients' lesions are located on non-cavity areas such as the foreskin, glans penis, labia majora, labia minora, with a number ranging from 1 to 5 individual lesions, and each individual lesion having a diameter less than 1 centimeter. * For female participants with reproductive capability, a negative pregnancy test result is mandatory at the screening stage. * Participants must volunteer to enroll in the study and be able to understand and sign a written informed consent form. Exclusion Criteria: * Pregnant women, breastfeeding mothers, or individuals planning to conceive during the study period. * Patients who received treatment for genital warts within two weeks prior to screening. * Patients with concurrent skin conditions in the affected area that might significantly impact the evaluation of treatment efficacy. * Individuals with known severe immunodeficiency or those requiring long-term use of corticosteroids and immunosuppressive agents. * Active carriers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or Treponema pallidum (syphilis). * Patients with a history of severe cardiovascular, hepatic, renal, endocrine, digestive, immune, respiratory, or nervous system diseases. * Patients with severe retinal disorders or other serious ophthalmologic conditions. * Patients allergic to interferons or excipients in the medication formulation, or those deemed unsuitable for CO2 laser treatment. * Individuals meeting any contraindications listed in the investigational drug's package insert. * Patients who participated in another interventional clinical trial within three months before screening, or those planning to participate in another clinical trial during the study period. * Other cases deemed inappropriate for enrollment by the investigator due to various reasons.

Locations (1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China